Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1997 Jun;91(2):197–203. doi: 10.1046/j.1365-2567.1997.00246.x

Inhibition of human interleukin-12 production by pentoxifylline.

D R Moller 1, M Wysocka 1, B M Greenlee 1, X Ma 1, L Wahl 1, G Trinchieri 1, C L Karp 1
PMCID: PMC1363847  PMID: 9227317

Abstract

Pharmacological control of interleukin-12 (IL-12) production may be a key therapeutic strategy for modulating immunological diseases dominated by type-1 cytokine responses. In this study, we investigated the effects of pentoxifylline on the production of IL-12 by human blood mononuclear cells and primary human monocytes stimulated with heat-killed Staphylococcus aureus Cowan strain I (SAC) or lipopolysaccharide (LPS). Pentoxifylline potently suppressed production of IL-12 in a concentration-dependent manner. In these same experiments, tumour necrosis factor-alpha (TNF-alpha) production was inhibited and IL-10 and prostaglandin E2 (PGE2) production was enhanced by treatment with pentoxifylline. Suppression of IL-12 production by pentoxifylline was found to be independent of several known endogenous inhibitors of IL-12, such as IL-10, transforming growth factor-beta (TGF-beta), IL-4 and PGE2. RNase protection assays revealed that pentoxifylline inhibited accumulation of both IL-12 p40 and p35 mRNA, suggesting a predominant mRNA locus for pentoxifylline-induced IL-12 inhibition. Low levels of pentoxifylline added to the suppression of IL-12 production by suboptimal inhibiting doses of dexamethasone, suggesting that this drug combination may have therapeutic utility. These results provide a firm rationale for the use of pentoxifylline in clinical trials of immunological disorders characterized by inappropriate type-1 immune responses.

Full text

PDF
197

Images in this article

200Figure 4
on p.200

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bertagnolli M. M., Lin B. Y., Young D., Herrmann S. H. IL-12 augments antigen-dependent proliferation of activated T lymphocytes. J Immunol. 1992 Dec 15;149(12):3778–3783. [PubMed] [Google Scholar]
  2. Bessler H., Gilgal R., Zahavi I., Djaldetti M. Effect of pentoxifylline on E-rosette formation and on the mitogenic response of human mononuclear cells. Biomed Pharmacother. 1987;41(8):439–441. [PubMed] [Google Scholar]
  3. Biswas D. K., Dezube B. J., Ahlers C. M., Pardee A. B. Pentoxifylline inhibits HIV-1 LTR-driven gene expression by blocking NF-kappa B action. J Acquir Immune Defic Syndr. 1993 Jul;6(7):778–786. [PubMed] [Google Scholar]
  4. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  5. Clerici M., Shearer G. M. A TH1-->TH2 switch is a critical step in the etiology of HIV infection. Immunol Today. 1993 Mar;14(3):107–111. doi: 10.1016/0167-5699(93)90208-3. [DOI] [PubMed] [Google Scholar]
  6. D'Andrea A., Ma X., Aste-Amezaga M., Paganin C., Trinchieri G. Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: priming for IL-12 and tumor necrosis factor alpha production. J Exp Med. 1995 Feb 1;181(2):537–546. doi: 10.1084/jem.181.2.537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. D'Andrea A., Rengaraju M., Valiante N. M., Chehimi J., Kubin M., Aste M., Chan S. H., Kobayashi M., Young D., Nickbarg E. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med. 1992 Nov 1;176(5):1387–1398. doi: 10.1084/jem.176.5.1387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dezube B. J., Eder J. P., Pardee A. B. Phase I trial of escalating pentoxifylline dose with constant dose thiotepa. Cancer Res. 1990 Nov 1;50(21):6806–6810. [PubMed] [Google Scholar]
  9. Forman J. D., Klein J. T., Silver R. F., Liu M. C., Greenlee B. M., Moller D. R. Selective activation and accumulation of oligoclonal V beta-specific T cells in active pulmonary sarcoidosis. J Clin Invest. 1994 Oct;94(4):1533–1542. doi: 10.1172/JCI117494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Germann T., Szeliga J., Hess H., Störkel S., Podlaski F. J., Gately M. K., Schmitt E., Rüde E. Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/1 mice. Proc Natl Acad Sci U S A. 1995 May 23;92(11):4823–4827. doi: 10.1073/pnas.92.11.4823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Han J., Thompson P., Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med. 1990 Jul 1;172(1):391–394. doi: 10.1084/jem.172.1.391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kammer G. M. The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol Today. 1988 Jul-Aug;9(7-8):222–229. doi: 10.1016/0167-5699(88)91220-0. [DOI] [PubMed] [Google Scholar]
  13. Landman D., Sarai A., Sathe S. S. Use of pentoxifylline therapy for patients with AIDS-related wasting: pilot study. Clin Infect Dis. 1994 Jan;18(1):97–99. doi: 10.1093/clinids/18.1.97. [DOI] [PubMed] [Google Scholar]
  14. Lechner A. J., Rouben L. R., Potthoff L. H., Tredway T. L., Matuschak G. M. Effects of pentoxifylline on tumor necrosis factor production and survival during lethal E. coli sepsis vs. disseminated candidiasis with fungal septic shock. Circ Shock. 1993 Apr;39(4):306–315. [PubMed] [Google Scholar]
  15. Leonard J. P., Waldburger K. E., Goldman S. J. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med. 1995 Jan 1;181(1):381–386. doi: 10.1084/jem.181.1.381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Locksley R. M. Interleukin 12 in host defense against microbial pathogens. Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):5879–5880. doi: 10.1073/pnas.90.13.5879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ma X., Chow J. M., Gri G., Carra G., Gerosa F., Wolf S. F., Dzialo R., Trinchieri G. The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J Exp Med. 1996 Jan 1;183(1):147–157. doi: 10.1084/jem.183.1.147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Maksymowych W. P., Avina-Zubieta A., Luong M. H., Russell A. S. An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis. J Rheumatol. 1995 Apr;22(4):625–629. [PubMed] [Google Scholar]
  19. Moller D. R., Forman J. D., Liu M. C., Noble P. W., Greenlee B. M., Vyas P., Holden D. A., Forrester J. M., Lazarus A., Wysocka M. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol. 1996 Jun 15;156(12):4952–4960. [PubMed] [Google Scholar]
  20. Murphy T. L., Cleveland M. G., Kulesza P., Magram J., Murphy K. M. Regulation of interleukin 12 p40 expression through an NF-kappa B half-site. Mol Cell Biol. 1995 Oct;15(10):5258–5267. doi: 10.1128/mcb.15.10.5258. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Navarro J., Punzón M. C., Pizarro A., Fernández-Cruz E., Fresno M., Muñoz-Fernández M. A. Pentoxifylline inhibits acute HIV-1 replication in human T cells by a mechanism not involving inhibition of tumour necrosis factor synthesis or nuclear factor-kappa B activation. AIDS. 1996 May;10(5):469–475. doi: 10.1097/00002030-199605000-00004. [DOI] [PubMed] [Google Scholar]
  22. Neurath M. F., Fuss I., Kelsall B. L., Stüber E., Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. 1995 Nov 1;182(5):1281–1290. doi: 10.1084/jem.182.5.1281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Perussia B., Chan S. H., D'Andrea A., Tsuji K., Santoli D., Pospisil M., Young D., Wolf S. F., Trinchieri G. Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cells. J Immunol. 1992 Dec 1;149(11):3495–3502. [PubMed] [Google Scholar]
  24. Reed W. R., DeGowin R. L. Suppressive effects of pentoxifylline on natural killer cell activity. J Lab Clin Med. 1992 Jun;119(6):763–771. [PubMed] [Google Scholar]
  25. Rieckmann P., Weber F., Günther A., Martin S., Bitsch A., Broocks A., Kitze B., Weber T., Börner T., Poser S. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J Neuroimmunol. 1996 Feb;64(2):193–200. doi: 10.1016/0165-5728(95)00176-x. [DOI] [PubMed] [Google Scholar]
  26. Rott O., Cash E., Fleischer B. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur J Immunol. 1993 Aug;23(8):1745–1751. doi: 10.1002/eji.1830230802. [DOI] [PubMed] [Google Scholar]
  27. Schwarz A., Krone C., Trautinger F., Aragane Y., Neuner P., Luger T. A., Schwarz T. Pentoxifylline suppresses irritant and contact hypersensitivity reactions. J Invest Dermatol. 1993 Oct;101(4):549–552. doi: 10.1111/1523-1747.ep12365951. [DOI] [PubMed] [Google Scholar]
  28. Seder R. A., Kelsall B. L., Jankovic D. Differential roles for IL-12 in the maintenance of immune responses in infectious versus autoimmune disease. J Immunol. 1996 Oct 1;157(7):2745–2748. [PubMed] [Google Scholar]
  29. Strieter R. M., Remick D. G., Ward P. A., Spengler R. N., Lynch J. P., 3rd, Larrick J., Kunkel S. L. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun. 1988 Sep 30;155(3):1230–1236. doi: 10.1016/s0006-291x(88)81271-3. [DOI] [PubMed] [Google Scholar]
  30. Thanhäuser A., Reiling N., Böhle A., Toellner K. M., Duchrow M., Scheel D., Schlüter C., Ernst M., Flad H. D., Ulmer A. J. Pentoxifylline: a potent inhibitor of IL-2 and IFN-gamma biosynthesis and BCG-induced cytotoxicity. Immunology. 1993 Sep;80(1):151–156. [PMC free article] [PubMed] [Google Scholar]
  31. Tilg H., Eibl B., Pichl M., Gächter A., Herold M., Brankova J., Huber C., Niederwieser D. Immune response modulation by pentoxifylline in vitro. Transplantation. 1993 Jul;56(1):196–201. doi: 10.1097/00007890-199307000-00036. [DOI] [PubMed] [Google Scholar]
  32. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol. 1995;13:251–276. doi: 10.1146/annurev.iy.13.040195.001343. [DOI] [PubMed] [Google Scholar]
  33. Wahl L. M., Katona I. M., Wilder R. L., Winter C. C., Haraoui B., Scher I., Wahl S. M. Isolation of human mononuclear cell subsets by counterflow centrifugal elutriation (CCE). I. Characterization of B-lymphocyte-, T-lymphocyte-, and monocyte-enriched fractions by flow cytometric analysis. Cell Immunol. 1984 May;85(2):373–383. doi: 10.1016/0008-8749(84)90251-x. [DOI] [PubMed] [Google Scholar]
  34. Ward A., Clissold S. P. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 1987 Jul;34(1):50–97. doi: 10.2165/00003495-198734010-00003. [DOI] [PubMed] [Google Scholar]
  35. Williamson E., Garside P., Bradley J. A., Mowat A. M. IL-12 is a central mediator of acute graft-versus-host disease in mice. J Immunol. 1996 Jul 15;157(2):689–699. [PubMed] [Google Scholar]
  36. Youinou P., Meroni P. L., Khamashta M. A., Shoenfeld Y. A need for standardization of the anti-endothelial-cell antibody test. Immunol Today. 1995 Aug;16(8):363–364. doi: 10.1016/0167-5699(95)80001-8. [DOI] [PubMed] [Google Scholar]
  37. Zabel P., Schade F. U., Schlaak M. Inhibition of endogenous TNF formation by pentoxifylline. Immunobiology. 1993 Apr;187(3-5):447–463. doi: 10.1016/S0171-2985(11)80356-6. [DOI] [PubMed] [Google Scholar]
  38. Zabel P., Wolter D. T., Schönharting M. M., Schade U. F. Oxpentifylline in endotoxaemia. Lancet. 1989 Dec 23;2(8678-8679):1474–1477. doi: 10.1016/s0140-6736(89)92929-2. [DOI] [PubMed] [Google Scholar]
  39. van der Pouw Kraan T. C., Boeije L. C., Smeenk R. J., Wijdenes J., Aarden L. A. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J Exp Med. 1995 Feb 1;181(2):775–779. doi: 10.1084/jem.181.2.775. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES